Stage IV Salivary Gland Cancer Completed Phase 1 / 2 Trials for Cetuximab (DB00002)

Also known as: Salivary gland cancer stage IV / Metastatic salivary gland cancer / Malignant salivary gland cancer stage IV

IndicationStatusPhase
DBCOND0028780 (Stage IV Salivary Gland Cancer)Completed1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00101348Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung CancerTreatment